Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

5.265 +0.045 (+0.86%)
Streaming Delayed Price Updated: 9:51 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpha Tau Medical Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Expert Ratings for Alpha Tau Medical ↗
 
Via Benzinga
News headline image
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish ↗
The company’s stock surged to a three-month high following its Q1 report, progress in FDA-approved clinical trials, and a recent capital raise. 
Via Stocktwits
News headline image
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ... 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023 ↗
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
News headline image
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.